Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors | Zendy

Amit Khatri | Zendy; Sandeep Dutta | Zendy; Haoyu Wang | Zendy; Thomas Podsadecki | Zendy; Roger Trinh | Zendy; Walid M. Awni | Zendy; Rajeev Me | Zendy

Open Access

Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors

Author(s) -

Amit Khatri,

Sandeep Dutta,

Haoyu Wang,

Thomas Podsadecki,

Roger Trinh,

Walid M. Awni,

Rajeev Me

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ1213

Subject(s) - dasabuvir , ritonavir , ombitasvir , paritaprevir , virology , drug , protease inhibitor (pharmacology) , medicine , pharmacology , human immunodeficiency virus (hiv) , chronic hepatitis , viral load , virus , ribavirin , antiretroviral therapy

Guidelines for the treatment of human immunodeficiency virus (HIV) infection consistently recommend initiation of antiretroviral therapy in patients with hepatitis C virus (HCV)/HIV-1 coinfection. Therefore, potential drug interactions between antiretroviral drugs and HCV direct-acting antiviral agents (DAAs) must be carefully considered. The objective of this investigation was to evaluate the compatibility of a novel combination of DAAs (the 3D regimen) with commonly prescribed HIV-1 protease inhibitors (PIs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research